Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB-121 (Scioto Biosciences, Inc.)
- Development stage
- Unknown
- Lead developer
- Scioto Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SB-121 is a live biotherapeutic product (LBP) being developed by Scioto Biosciences for the treatment of Autism Spectrum Disorder (ASD). The drug utilizes the company's proprietary Activated Bacterial Therapeutics (ABT) platform, which involves priming the probiotic bacterium *Lactobacillus reuteri* to form a biofilm on polysaccharide microspheres (Sephadex). This 'biofilm-primed' state is intended to enhance the survival, delivery, and colonization of the bacteria within the gastrointestinal tract compared to standard probiotic formulations. SB-121 targets the gut-brain axis; specifically, *L. reuteri* is known to stimulate the production and release of oxytocin via the vagus nerve. By increasing oxytocin levels, SB-121 aims to improve social communication and behavioral symptoms in individuals with autism.
- Other names
- Lactobacillus reuteri formulationLactobacillus Reuteri With Sephadex and Maltose
02
Targets
Oxytocin receptor
Beyond the preview
Go deeper on SB-121 (Scioto Biosciences, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB-121 (Scioto Biosciences, Inc.).